Please Wait
Applying Filters...
Menu
Xls

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
Aclaris lays off 46%, resurrects zunsemetinib for cancer
Aclaris lays off 46%, resurrects zunsemetinib for cancer

20 Dec 2023

// James Waldron FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/aclaris-lays-46-staff-resurrects-zunsemetinib-potential-cancer-treatment

James Waldron FIERCE BIOTECH
20 Dec 2023

https://www.globenewswire.com//news-release/2023/11/13/2778890/37216/en/Aclaris-Therapeutics-Announces-Top-line-Results-from-12-Week-Phase-2b-Trial-of-Oral-Zunsemetinib-ATI-450-for-Moderate-to-Severe-Rheumatoid-Arthritis-and-Provides-Corporate-Update.html

GLOBENEWSWIRE
13 Nov 2023

https://www.globenewswire.com/news-release/2023/06/13/2687010/37216/en/Aclaris-Therapeutics-Completes-Enrollment-in-Phase-2b-Study-of-Oral-Zunsemetinib-ATI-450-for-Moderate-to-Severe-Rheumatoid-Arthritis-ATI-450-RA-202.html

GLOBENEWSWIRE
13 Jun 2023